摘要
目的 :探讨缬沙坦与非洛地平对照治疗脑梗死的临床疗效和安全性。方法 :6 8例脑梗死患者随机分成研究组和对照组 ,2组基础治疗相同 ,研究组在此基础上加用缬沙坦 80mg ,qd ,连用 4周为 1个疗程 ;对照组应用非洛地平 5mg ,qd ,连用 4周为 1个疗程。 2组在治疗前后均进行神经功能缺损程度评分和疗效评定。 结果 :缬沙坦能减少脑梗死患者的神经功能缺损程度评分 ;治疗脑梗死有效率为 88.2 4%,与对照组 (70 .5 9%)相比差异有显著性 (P <0 .0 5 )。且不良反应少且轻微。结论 :缬沙坦能降低脑梗死患者的神经功能缺损程度评分 ,治疗脑梗死安全有效。
Objective:To investigate the efficacy and safety of valsartan in the treatment of ischemic cerebral infarction.Methods:68 patients with ischemic cerebral infarction within the first 72 hours after the onset of the disease were randomly divided into active study and control group.The active group were given valsartn 80mg,qd,po for 4 weeks.The control group received felodipine 5mg,qd for 4 weeks.Neurologic deficit degree score was examined and the efficacy and safety were evaluated.Results:Valsartan can reduce neurologic deficit scores of the patients with ischemic cerebral infarction(P<0.05). The total effective rate is 88.24% for valsartan in the treatment of cerebral infarction,and there was significant difference than control group(P<0.05).The side-effect is light.Conclusion:Valsartan is a new safe drug that has curative effect and reliable in treatment of cerebral infarction.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2002年第1期84-87,共4页
Chinese Journal of New Drugs
